<DOC>
	<DOCNO>NCT00214773</DOCNO>
	<brief_summary>The objective program : characterize natural progression MPS VI disease ; generate disseminate information care management MPS VI patient clinical medical professional ; provide resource physician patient provide information optimize patient care base aggregate data ; characterize clinical response long-term Naglazyme® ( galsulfase ) treatment ; characterize long-term safety Naglazyme® treatment .</brief_summary>
	<brief_title>Mucopolysaccharidosis ( MPS ) VI Clinical Surveillance Program ( CSP )</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Inclusion Criteria All patient must meet follow criterion qualify enrollment CSP : Patient patient 's parent legal guardian , child 18 year old unable consent , provide sign Patient Information Authorization Form . Patient laboratory result confirm diagnosis MPS VI disease base detection deficient ARSB activity ( fibroblast , leucocyte dry blood spot ) and/or abnormality ARSB gene . Patient willing undergo general assessment establish baseline data permit physician enter assessment data record prior CSP entry available patient 's medical record . General assessment include : urinary GAG level , urinary protein level , serum sample antibody level , height , weight , patient history .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>